agents in obstructive peripheral arterial disease? Intravenous streptokinase clears about 80% of occlusions treated within 12 hours although, if treatment is delayed for up to three days, only 60% are dissolved.' In old obstructions the success rate is much lower and almost no lysis is obtained if thrombi have been present for over three months in the iliac or femoral arteries." Frequent and serious haemorrhagic complications are common with this treatment, with mortality rates ranging from between 1% and 3% in various series." Intravenous tPA, whilst appearing safer in one small study, was however ineffective."
Low-dose intra-arterial thrombolytic therapy does appear to be the regimen of choice for treatment of peripheral arterial occlusions. Over 25 years ago McNicol et al.' used a local intra-arterial streptokinase infusion to treat a patient with peripheral artery disease. Dotter et al. s extended this work in 1974 when they attempted to provide local thrombolysis and avoid a systemic lytic state. Local treatment with low-dose streptokinase or urokinase infused into the blood clot is successful in about 50-80% of patients 9 • 1o and recanalization is sustained for up to one year in approximately 50%.11 However, although the doses used in thrombolytic therapy are low (urokinase 60000 IV/h or streptokinase 5000 IV/h), the risk of minor bleeding is 15-20% and of major haemorrhage 10%. 12 Ricotta et al. 13 collected the results of 623 patients who had been treated outside clinical trials. The success rate (defined as reperfusion resulting in a viable limb) was 50% but there were serious complications in 20% including mortality rate of 2.3%, stroke (1.4%) and leg amputation (15%). These findings may reflect everyday experience more accurately than trials in specialized vascular centres.
Patient selection
The safety and success of local intra-arterial thrombolysis are critically dependent on patient selection. Overall the fresher the thrombus the more easily it is lysed. A simple test is to pass the guidewire into the thrombus. A fresh thrombus which is amenable to lysis can be assured if passage of the guidewire is easy. No fixed ground rules have been established but, in general, obstructions are no longer lysable in the small digital arteries after a few days, in lower leg or arm after a few weeks, and in brachial, popliteal or femoral arteries after two to four months. Thrombosis of the iliac vessels or abdominal aorta may respond after six months.w If an embolus is being lysed its source may be important, as organized thrombus from the heart or aorta may be more difficult to lyse than in situ thrombus which may be more recently formed. Although substantial lysis can be achieved even with large clots, short occlusions are more rapidly dissolved than the long ones. The nature of the initial lesion is also important; for example, proximal emboli into which the catheter can be embedded are more easily lysed than distal lesions. This is probably related to the fact that the infusage is more dilute by the time it reaches the thrombus or may have passed outwith the area through other vessels which do not feed to the clot. Absolute contraindications are factors that could contribute to intracranial bleeding such as a recent history of stroke or transient ischaemic attacks, other intracranial lesions, or uncontrolled hypertension. The guidelines for patient selection are broadly the same as those for myocardial infarction and must be strictly adhered tol. The major risk associated with the use of thrombolytic agents is haemorrhage. Thus it is important that the platelet count, fibrinogen levels, prothrombin time and partial thromboplastin time should be normal before treatment has begun. Thrombolytic agents are useful when used in patients with obstructed vascular grafts.t? However, Dacron grafts are not suitable for thrombolytic treatment within one year of placement because endothelialization is variable and the graft integrity may depend on thrombosis between the fibres. A recent (less than 48 hours) postoperative thrombosis of a vascular graft usually suggests a technical problem indicating that thrombectomy and concurrent surgical correction are required. 16 Additionally, thrombolysis so soon after surgery is contraindicated because of the risk of haemorrhage.
Practical application of intra-arterial thrombolytic therapy: streptokinase and urokinase
Diagnostic angiography should be carried out if there are no contraindications to treatment. As bleeding from recent puncture sites is a common complication of thrombolytic therapy, it is routine practice to initiate the therapy during the diagnostic procedure. There are two low-dose regimens for streptokinase and urokinase. In the first, either 5000 IVIh streptokinase or 60000 IVIh urokinase is infused directly into the clot, perferably with advancement of the catheter into the lysing clot every six to eight hours. In the second regimen intrathrombus injections of 1000 IV streptokinase or 25 000 IV urokinase are repeated every five minutes.P-P Between injections, the catheter is advanced until the thrombus is completely infiltrated.
The second technique produces more rapid thrombolysis (between one and seven hours), but complications are increased because the cumulative dose is higher. Occasionally, a combination of approaches can be employed where the clot is initially infiltrated with a bolus dose of 5000 IV streptokinase and continued with the same dose given hourly. Repeated angiograms can be used to assess progress. However, if no lysis has occurred within the first 24 hours the procedure is unlikely to be successful. If thrombolysis is occurring the infusion may be continued; some researchers have continued for up to six days.s-?
Laboratory monitoring
During treatment, laboratory monitoring can confirm activation of fibrinolysis. However, it tells us nothing about clot lysis." In general, however, if the treatment does not produce any elevation in fibrin degradation product it is unlikely to be producing much lysis. It has also been suggested that monitoring of the coagulation indices does not predict haemorrhagic complications.P Our group do not agree with this and have found the measurement of fibrinogen and fibrin degradation products every four to six hours very useful indeed. Occasionally thrombolysis will be stopped for a short time period until coagulation normalizes in patients thought to be at risk of haemorrhage, with later resumption of the treatment. In most centres the dose of thrombolytic therapy would be decreased orJreatment stopped if the fibrinogen level fell to less than 1 gll.1S The most useful determinants of the fibrinolytic state are the thrombin time and fibrinogen levels. Estimations of packed cell volume are helpful if the infusion is continued for a long time. Some centres estimate these variables every six to eight hours while others are content with 12-24 hours.
Management following intra-arterial thrombolysis: adjunctive therapy
It is imperative that repeat angiography should be carried out after completion of thrombolytic therapy in order that underlying abnormalities which caused the original occlusion may be identified. These lesions may be amenable to balloon angioplasty or indeed surgical repair. The chosen procedure should be carried out as soon as possible to avoid rethrombosis which occurs in about 1G-30% of patients.w Most workers, therefore, recommend some form of adjunctive antithrombotic therapy. Pretreatment with aspirin starting the day before the procedure if possible and continuing thereafter has been used.P whereas others recommend full systemic anticoagulation with heparin once the fibrinogen level is above 1 gil or after four hours if the fibrinogen level is normal, followed by warfarin. IS Unfortunately, no data are available as to the relative merits of each approach. A sensible compromise is to pretreat all suitable patients with aspirin and reserve full anticoagulation for patients with evidence of an underlying lesion which cannot be immediately rectified or who have poor distal run-off. Complications other than bleeding include embolization distal to the thrombus and pericatheter thrombosis, which can usually be treated by continued thrombolytic therapy.
All workers are agreed that the arterial catheter should be removed immediately after cessation of lytic therapy. As a check angiogram must be carried out after lysis, it is our usual procedure to insert the catheter initially with a surrounding sheath. When thrombolysis is terminated, either because the patient has clinically reperfused or because of disordered coagulation/bleeding, the catheter can be removed thus preventing the risk of catheter thrombosis, yet access is preserved for later arteriography.
Some authors suggest that patients with vascular grafts should be given prophylactic antibiotics to avoid graft infection, and it has been considered that this is a particular risk when the catheter is being advanced down through the clot. Lysis should not be attempted when reperfusion of the ischaemic limb is likely to produce the 'crush syndrome' with myoglobinuria and renal failure. 19 Intra-arterial tPA and anistreplase Low-dose, intra-arterial tPA has also been assessed. Graor and Olinw report the results of the Cleveland Clinic treating 65 patients with a tPA infusion in a dose of 0.1 mg/h or 0.05 mg/h in a four to eight hour infusion with a mean time of five and a quarter hours. Equal reperfusion was obtained in both groups with a success rate exceeding those usually reported for streptokinase. Serious side-effects were, however, more common with the higher doses. The incidence of major bleeding events can be decreased by lowering the dose of tPA. Verstraete et al. 20 in the Collaborative European Study confirmed that efficacy was retained even when the dose of tPA was reduced from 10 mg/h to 5 mg/h and then 3 mglh/. With the infusion being maintained for five to eight hours in patients with femoral and popliteal occlusions, 86% recanalization was obtained. The most popular dose range for tPA is 0.5-1 mg/h given to a maximum dose of 100 mg. Higher doses can cause severe haemorrhage. In general, successful thrombolysis is achieved in 68-94% of patients-! with severe complications in 6-17%; most adverse events occur at doses above 1 mglh. 9, 22, 23 Tissue plasminogen activator has been compared with streptokinase in one study-' in which lysis occurred more quickly after tPA. There were similar haemorrhagic complications in the two groups although this comparison may not be fair because the dose of tPA was higher than usual. Meyerovitz et al. 24 randomized patients with blocked grafts to receive either tPA or urokinase. There was a trend to earlier thrombolysis with the tPA group (p <0.04) at eight hours but this was lost by 24 hours. In this study long thrombi were lysed (means 44 and 42 em, respectively) and this may account for the relatively low reperfusion incidence of approximately 50%. There was major bleeding in five of the tPA patients which may reflect the higher than usual dosage schedule.
Little information is available concerning the effect of anistreplase on arterial occlusion. One study showed successful thrombolysis in only 24% of patients following an intravenous bolus injection of 5 mg anistreplase every eight hours over 72 hours. 2s However, the present available information is inadequate to evaluate the use of this compound in this clinical indication.
Conclusion
Thrombolytic therapy is a potentially promising treatment for noncoronary arterial thrombosis. Clinical experience of peripheral arterial disease suggests a role for such treatment in selected patients. However, there is the need for further well-structured clinical studies. It is imperative that thrombolytic treatment be compared to surgical intervention and a study assessing this is currently underway using tPA. Furthermore, streptokinase, urokinase, tPA and anistreplase should be compared in a prospective randomized double-blind trial. The successful implementation of this promising therapy is likely to rely on close cooperation between vascular surgeons, radiologists and angiologists.
